Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
MORE►
RNA
Daniel Siegwart, Ph.D., is Director of the Program in Genetic Drug Engineering, Professor of Biomedical Engineering and Biochemistry, and a member of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern. [Photo: UT Southwestern]
UT Southwestern Collaborates With Pfizer to Develop Better RNA Delivery Tech
by Lance Murray | Feb 13, 2024
UT Southwestern Medical Center and pharmaceutical company Pfizer have teamed up to develop new ways to deliver genetic treatments to patients.
Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
Together they aim to accelerate the development of therapies that work through RNA biology and engineered delivery methods to fix root genetic causes of disease, which Pfizer could apply to its portfolio of investigational programs.
by Lance Murray |
Jan 23, 2023
Caris Life Sciences, the Irving-based biotech company, announced Thursday that it closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell, bringing its funding total since 2018 to roughly $1.7 billion....
MORE►
